Related Experiment Video
Updated: Nov 22, 2025
06:26
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
1.5K
Biologics for atopic diseases: Indication, side effect management, and new developments.
Uta Jappe1,2, Hendrik Beckert3, Karl-Christian Bergmann4
1Research Group Clinical and Molecular Allergology of the Research Center Borstel, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL).
Allergologie Select
|January 11, 2021
Summary
Biologicals offer targeted treatments for immune-driven diseases like severe asthma and atopic dermatitis. Effective use requires precise patient phenotyping and consideration of combination therapies, side effects, and pre-treatment immune status.
Area of Science:
- Immunology
- Pharmacology
- Dermatology
Background:
- Biologicals are increasingly used for immune-mediated diseases.
- Precision medicine tailors therapy to individual patient characteristics.
- Atopic diseases like severe asthma, urticaria, atopic dermatitis, and chronic rhinosinusitis with nasal polyps have seen approvals for biological therapies.
Purpose of the Study:
- To discuss the role of biologicals in treating atopic diseases.
- To highlight the importance of clinical and immunological phenotyping for treatment response.
- To address challenges in combination biological therapy, side effect management, and special patient populations.
Main Methods:
- Review of current literature on biological therapies for atopic diseases.
- Discussion of diagnostic and management strategies for complex cases.
- Emphasis on patient phenotyping and immune status assessment.
Main Results:
- Treatment response to biologicals correlates with accurate patient phenotyping.
- Combination biological therapies are emerging for complex atopic conditions.
- Management requires careful consideration of side effects, hypersensitivity, pregnancy, vaccinations, and infections like SARS-CoV-2.
Conclusions:
- Precise phenotyping is crucial for optimizing biological therapy in atopic diseases.
- Further research is needed on combination therapies, side effect detection, and predicting treatment response.
- Assessing immune status and vaccination status before initiating biologicals is essential.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
117
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
117
01:29Inflammatory Bowel Disease IV: Pharmacological Management
302
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
302
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
302
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
302
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.5K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.5K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
323
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
323
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
296
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
296